Published in J Clin Invest on September 01, 1973
Variant von Willebrand's disease: characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets. J Clin Invest (1980) 2.88
Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. J Clin Invest (1977) 1.85
Studies on human antihemophilic factor. Evidence for a covalently linked subunit structure. J Clin Invest (1976) 1.56
Substructure of human von Willebrand factor. J Clin Invest (1985) 1.55
Demonstration and characterization of specific binding sites for factor VIII/von Willebrand factor on human platelets. J Clin Invest (1979) 1.55
Disulfide bonds and the quaternary structure of factor VIII/von Willebrand factor. J Clin Invest (1978) 1.48
Studies on the mechanism of ristocetin-induced platelet agglutination. Effects of structural modification of ristocetin and vancomycin. J Clin Invest (1977) 1.21
Studies of the human factor VIII/von Willebrand factor protein. III. Qualitative defects in von Willebrand's disease. J Clin Invest (1975) 1.03
The defect in hemophilic and von Willebrand's disease plasmas studied by a recombination technique. J Clin Invest (1974) 0.95
Effects of thrombin treatment of preparations of factor VIII and the Ca2+-dissociated small active fragment. J Clin Invest (1975) 0.94
Platelet receptors for human Factor VIII/von Willebrand protein: functional correlation of receptor occupancy and ristocetin-induced platelet aggregation. Proc Natl Acad Sci U S A (1979) 0.91
Electron microscopy of human factor VIII/Von Willebrand glycoprotein: effect of reducing reagents on structure and function. J Cell Biol (1982) 0.88
Macromolecular factor VIII complex: functional and structural heterogeneity observed in von Willebrand swine with transfusion. Proc Natl Acad Sci U S A (1977) 0.86
Role of carbohydrate in multimeric structure of factor VIII/von Willebrand factor protein. Proc Natl Acad Sci U S A (1983) 0.82
Some effects of calcium on the activation of human factor VIII/Von Willebrand factor protein by thrombin. J Clin Invest (1977) 0.80
Subunit structure and assembly of von Willebrand factor polymer: complementary analysis by electron microscopy and quasielastic light scattering. Biophys J (1986) 0.76
Protein measurement with the Folin phenol reagent. J Biol Chem (1951) 1743.91
The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis. J Biol Chem (1969) 142.11
EQUILIBRIUM ULTRACENTRIFUGATION OF DILUTE SOLUTIONS. Biochemistry (1964) 24.14
Glycoprotein staining following electrophoresis on acrylamide gels. Anal Biochem (1969) 12.65
A simple ultraviolet spectrophotometric method for the determination of protein. J Lab Clin Med (1956) 9.66
Effect of antihemophilic factor on one-stage clotting tests; a presumptive test for hemophilia and a simple one-stage antihemophilic factor assy procedure. J Lab Clin Med (1953) 5.13
The estimation of polypeptide chain molecular weights by gel filtration in 6 M guanidine hydrochloride. J Biol Chem (1969) 4.77
Human Factor XIII from plasma and platelets. Molecular weights, subunit structures, proteolytic activation, and cross-linking of fibrinogen and fibrin. J Biol Chem (1973) 2.45
Factor 8 detection by hemagglutination inhibition: hemophilia A and von Willebrand's disease. Science (1971) 2.27
Subunit structure of human fibrinogen, soluble fibrin, and cross-linked insoluble fibrin. Proc Natl Acad Sci U S A (1970) 2.24
Studies on the purification and characterization of human factor 8. J Clin Invest (1972) 1.97
The isolation nd characterization of bovine factor VIII (antihemophilic factor). J Biol Chem (1972) 1.66
Studies on the purification of antihemophilic factor (factor 8. I. Precipitation of antihemophilic factor by concanavalin A. J Clin Invest (1969) 1.64
Methods for the production of clinically effective intermediate- and high-purity factor-VIII concentrates. Br J Haematol (1971) 1.64
THE POLYPEPTIDE CHAINS OF RABBIT GAMMA-GLOBULIN AND ITS PAPAIN-CLEAVED FRAGMENTS. Biochemistry (1964) 1.56
Microheterogeneity of L-amino acid oxidase. Separation of multiple components by polyacrylamide gel electrofucusing. J Biol Chem (1969) 1.53
Isopiestic compositions as a measure of preferential interactions of macromolecules in two-component solvents. Application to proteins in concentrated aqueous cesium chloride and guanidine hydrochloride. J Am Chem Soc (1967) 1.45
Immunological differentiation of three types of haemophilia and identification of some female carriers. Lancet (1970) 1.43
Immunologic studies of antihemophilic factor (AHF, factor VIII): cross-reacting material in a genetic variant of hemophilia A. Blood (1968) 1.40
Polypeptide chains from human red blood cell membranes. J Biol Chem (1971) 1.36
Myosin structure as revealed by simultaneous electrophoresis of heavy and light subunits. Biochemistry (1970) 1.36
Studies on the purification of antihemophilic factor (factor VIII). II. Separation of partially purified antihemophilic factor by gel filtration of plasma. J Clin Invest (1969) 1.33
Purification of human antihemophilic factor (factor VIII) by gel chromatography. Biochim Biophys Acta (1970) 1.32
The effect of fibrin-stabilizing factor on the subunit structure of human fibrin. J Clin Invest (1971) 1.22
Isolation and some chemical properties of human factor VIII (antihemophilic factor). J Lab Clin Med (1971) 1.20
A clinical and experimental study of acquired inhibitors to factor 8. Blood (1965) 1.18
Formation of intrinsic factor-X activator activity, with special reference to the role of thrombin. Br J Haematol (1971) 1.16
THE MOLECULAR WEIGHT OF THE POLYPEPTIDE CHAINS OF L-GLUTAMATE DEHYDROGENASE. J Biol Chem (1964) 1.05
Purification of antihemophilic factor (AHF) for clinical and experimental use. Thromb Diath Haemorrh Suppl (1967) 0.96
A simple method for the purification of factor VIII (antihemophilic factor) employing snake venom. J Lab Clin Med (1971) 0.86
The natural history of congestive heart failure: the Framingham study. N Engl J Med (1971) 13.94
Role of blood pressure in the development of congestive heart failure. The Framingham study. N Engl J Med (1972) 2.91
Human Factor XIII from plasma and platelets. Molecular weights, subunit structures, proteolytic activation, and cross-linking of fibrinogen and fibrin. J Biol Chem (1973) 2.45
Subunit structure of human fibrinogen, soluble fibrin, and cross-linked insoluble fibrin. Proc Natl Acad Sci U S A (1970) 2.24
Clearance and binding of two electrophoretic "fast" forms of human alpha 2-macroglobulin. J Biol Chem (1981) 2.15
Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci U S A (1999) 1.95
Hepatic receptor that specifically binds oligosaccharides containing fucosyl alpha1 leads to 3 N-acetylglucosamine linkages. Proc Natl Acad Sci U S A (1978) 1.87
Effector mechanisms of cytolytically activated macrophages. II. Secretion of a cytolytic factor by activated macrophages and its relationship to secreted neutral proteases. J Immunol (1980) 1.85
Endothelial cell surface F1-F0 ATP synthase is active in ATP synthesis and is inhibited by angiostatin. Proc Natl Acad Sci U S A (2001) 1.83
Physical conditioning augments the fibrinolytic response to venous occlusion in healthy adults. N Engl J Med (1980) 1.81
Model of alpha 2-macroglobulin structure and function. Proc Natl Acad Sci U S A (1985) 1.79
Comparison of polyclonal antiserum versus monoclonal antibodies for the rapid diagnosis of influenza A virus infections by immunofluorescence in clinical specimens. J Clin Microbiol (1985) 1.65
Career characteristics of graduates of a Medical Scientist Training Program, 1970-1990. Acad Med (1996) 1.58
Studies on human antihemophilic factor. Evidence for a covalently linked subunit structure. J Clin Invest (1976) 1.56
Substructure of human von Willebrand factor. J Clin Invest (1985) 1.55
Demonstration and characterization of specific binding sites for factor VIII/von Willebrand factor on human platelets. J Clin Invest (1979) 1.55
The binding of human plasminogen to fibrin and fibrinogen. J Biol Chem (1983) 1.53
Oxidative dissociation of human alpha 2-macroglobulin tetramers into dysfunctional dimers. J Biol Chem (1994) 1.53
Enhancement of fibrinolysis by inhibiting enzymatic cleavage of precursor α2-antiplasmin. J Thromb Haemost (2011) 1.51
Physical properties of human alpha 2-macroglobulin following reaction with methylamine and trypsin. Biochim Biophys Acta (1982) 1.49
Measles spread in medical settings: an important focus of disease transmission? Pediatrics (1987) 1.48
Relationship of sialic acid to function and in vivo survival of human factor VIII/von Willebrand factor protein. J Biol Chem (1977) 1.47
Selective diminution of the binding of mannose by murine macrophages in the late stages of activation. J Biol Chem (1982) 1.45
The effect of plasmin on the subunit structure of human fibrinogen. J Biol Chem (1972) 1.44
Immunochemical and biochemical characterization of a glioma-associated extracellular matrix glycoprotein. J Cell Biochem (1985) 1.42
alpha 2-Macroglobulin, complement, and biologic defense: antigens, growth factors, microbial proteases, and receptor ligation. Lab Invest (1994) 1.33
Receptors for maleylated proteins regulate secretion of neutral proteases by murine macrophages. Science (1982) 1.31
The subunit structures of human plasma and platelet factor XIII (fibrin-stabilizing factor). J Biol Chem (1971) 1.30
Downregulation of microglial activation by apolipoprotein E and apoE-mimetic peptides. Exp Neurol (2001) 1.29
Analysis of inter-alpha-trypsin inhibitor and a novel trypsin inhibitor, pre-alpha-trypsin inhibitor, from human plasma. Polypeptide chain stoichiometry and assembly by glycan. J Biol Chem (1989) 1.29
Further characterization of the cellular plasminogen binding site: evidence that plasminogen 2 and lipoprotein a compete for the same site. Biochemistry (1989) 1.28
The subunit polypeptides of human fibrinogen. Arch Biochem Biophys (1966) 1.24
Postural responses to lateral perturbation in healthy subjects and ankle sprain patients. Med Sci Sports Exerc (1992) 1.24
The clinical validity of normal compression ultrasonography in outpatients suspected of having deep venous thrombosis. Ann Intern Med (1998) 1.23
Pertussis epidemic in Oklahoma. Difficulties in preventing transmission. Am J Dis Child (1986) 1.23
The effect of fibrin-stabilizing factor on the subunit structure of human fibrin. J Clin Invest (1971) 1.22
Carbohydrate composition and identification of blood group A, B, and H oligosaccharide structures on human Factor VIII/von Willebrand factor. J Biol Chem (1979) 1.21
Spurious hypertension in the obese patient. Effect of sphygmomanometer cuff size on prevalence of hypertension. Arch Intern Med (1984) 1.20
Methionine sulfoxide and the oxidative regulation of plasma proteinase inhibitors. J Leukoc Biol (1988) 1.20
Effects of bacterial lipopolysaccharide on the hydrolysis of phosphatidylinositol-4,5-bisphosphate in murine peritoneal macrophages. J Immunol (1987) 1.19
Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the alpha2beta1 integrin. Int J Cancer (1996) 1.19
A new procedure for the synthesis of polyethylene glycol-protein adducts; effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and alpha 2-macroglobulin. Anal Biochem (1983) 1.19
Non-Hodgkin's lymphomas in leukemic phase: clinicopathologic correlations. Am J Med (1980) 1.19
Immunohistochemical detection of factor VIII/von Willebrand factor in hyperplastic endothelial cells in glioblastoma multiforme and mixed glioma-sarcoma. J Neuropathol Exp Neurol (1982) 1.18
Intramuscular temperature responses in the human leg to two forms of cryotherapy: ice massage and ice bag. J Orthop Sports Phys Ther (1998) 1.17
Chondroitin 4-sulfate covalently cross-links the chains of the human blood protein pre-alpha-inhibitor. J Biol Chem (1991) 1.16
Clinical fracture of the carpal scaphoid--supportive bandage or plaster cast immobilization? J Hand Surg Br (1988) 1.16
Specificity and sensitivity of immunohistochemical detection of factor VIII/von Willebrand factor antigen in formalin-fixed paraffin-embedded tissue. J Histochem Cytochem (1982) 1.10
Precipitation of fibrinogen, fibrinogen degradation products and fibrin monomer by histone H3. Thromb Res (1985) 1.09
Ligand binding, conformational change and plasma elimination of human, mouse and rat alpha-macroglobulin proteinase inhibitors. Biochem J (1983) 1.08
Molecular structural studies of human factor VIII. Ann N Y Acad Sci (1975) 1.08
The conformation-dependent interaction of alpha 2-macroglobulin with vascular endothelial growth factor. A novel mechanism of alpha 2-macroglobulin/growth factor binding. J Biol Chem (2000) 1.08
Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. Int J Cancer (1994) 1.08
Binding of alpha 2-macroglobulin to hepatocytes: mechanism of in vivo clearance. Biochem Biophys Res Commun (1985) 1.07
Presence of the protein-glycosaminoglycan-protein covalent cross-link in the inter-alpha-inhibitor-related proteinase inhibitor heavy chain 2/bikunin. J Biol Chem (1993) 1.05
The extracellular matrix proteins laminin and fibronectin contain binding domains for human plasminogen and tissue plasminogen activator. J Biol Chem (1993) 1.05
Catabolism of human tissue plasminogen activator in mice. Blood (1985) 1.05
Amyloid precursor protein and amyloid beta-peptide bind to ATP synthase and regulate its activity at the surface of neural cells. Mol Psychiatry (2007) 1.04
Effects of plasmin on von Willebrand factor multimers. Degradation in vitro and stimulation of release in vivo. J Clin Invest (1985) 1.03
Implementation and evaluation of an interdisciplinary health professions core curriculum. J Allied Health (1999) 1.03
The effect of plasmin on the subunit structure of human fibrin. J Biol Chem (1973) 1.03
The in vivo metabolism of antithrombin III and antithrombin III complexes. J Biol Chem (1982) 1.03
The effects of 12 weeks of beta-hydroxy-beta-methylbutyrate free acid supplementation on muscle mass, strength, and power in resistance-trained individuals: a randomized, double-blind, placebo-controlled study. Eur J Appl Physiol (2014) 1.02
Catabolic pathways for streptokinase, plasmin, and streptokinase activator complex in mice. In vivo reaction of plasminogen activator with alpha 2-macroglobulin. J Clin Invest (1982) 1.01
Selective upregulated expression of the alpha2-macroglobulin signaling receptor in highly metastatic 1-LN prostate carcinoma cells. Arch Biochem Biophys (2000) 1.00
Test-retest reliability of reciprocal isokinetic knee extension and flexion peak torque measurements. J Athl Train (1992) 1.00
Substructure of human von Willebrand factor. Proteolysis by V8 and characterization of two functional domains. J Biol Chem (1986) 0.99
Receptor-mediated antigen delivery into macrophages. Complexing antigen to alpha 2-macroglobulin enhances presentation to T cells. J Immunol (1993) 0.99
Modulation of the unfolded protein response in prostate cancer cells by antibody-directed against the carboxyl-terminal domain of GRP78. Apoptosis (2010) 0.98
In vivo catabolism of alpha 1-proteinase inhibitor-trypsin, antithrombin III-thrombin and alpha 2-macroglobulin-methylamine. Biochim Biophys Acta (1982) 0.98
Apolipoprotein E and mimetic peptide initiate a calcium-dependent signaling response in macrophages. J Leukoc Biol (2001) 0.97
Structure of inter-alpha-inhibitor (inter-alpha-trypsin inhibitor) and pre-alpha-inhibitor: current state and proposition of a new terminology. Biol Chem Hoppe Seyler (1990) 0.97
The relationship between low density lipoprotein-related protein/alpha 2-macroglobulin (alpha 2M) receptors and the newly described alpha 2M signaling receptor. J Biol Chem (1994) 0.97
Atrophie blanche. A disorder associated with defective release of tissue plasminogen activator. Arch Pathol Lab Med (1986) 0.96
Activation of human plasminogen by urokinase. Partial characterization of a pre-activation peptide. J Biol Chem (1974) 0.96
Characterization of functional human alpha 2-macroglobulin half-molecules isolated by limited reduction with dithiothreitol. Biochemistry (1983) 0.96
Short-term pulmonary effects of total parenteral nutrition in children with cystic fibrosis. J Pediatr (1984) 0.96
Mechanism of insulin incorporation into alpha 2-macroglobulin: implications for the study of peptide and growth factor binding. Biochemistry (1991) 0.96
A plasma membrane-associated component of ovarian adenocarcinoma cells enhances the catalytic efficiency of matrix metalloproteinase-2. J Biol Chem (1995) 0.95
The potential role of alpha 2-macroglobulin in the control of cysteine proteinases (gingipains) from Porphyromonas gingivalis. J Periodontal Res (1997) 0.95
Plasmin binding to the plasminogen receptor enhances catalytic efficiency and activates the receptor for subsequent ligand binding. Arch Biochem Biophys (1991) 0.95
Functional inactivation and structural disruption of human alpha 2-macroglobulin by neutrophils and eosinophils. J Biol Chem (1989) 0.95
Conformation and protease binding activity of binary and ternary human alpha 2-macroglobulin-protease complexes. J Biol Chem (1983) 0.94
Chemical and structural modifications of alpha 2-macroglobulin: effects on receptor binding and endocytosis studied in an in vivo model. Ann N Y Acad Sci (1983) 0.94
Oxidized alpha2-macroglobulin (alpha2M) differentially regulates receptor binding by cytokines/growth factors: implications for tissue injury and repair mechanisms in inflammation. J Immunol (1998) 0.94
Alpha-macroglobulin from Limulus polyphemus exhibits proteinase inhibitory activity and participates in a hemolytic system. Biochemistry (1990) 0.94
Localization of factor VIII/von Willebrand factor and glial fibrillary acidic protein in the hemangioblastoma: implications for stromal cell histogenesis. Acta Neuropathol (1982) 0.93
Proteinase binding and inhibition by the monomeric alpha-macroglobulin rat alpha 1-inhibitor-3. J Biol Chem (1989) 0.92
Changes in the binding of "fast"-form alpha 2-macroglobulin to 3T3-L1 cells after differentiation to adipocytes. Biochemistry (1984) 0.92
Defective release of tissue plasminogen activator in systemic and cutaneous vasculitis. Am J Med (1987) 0.92